BIAYA PENGGUNAAN OBAT HIPOGLIKEMIK ORAL (OHO) METFORMIN DAN GLIMEPIRID PADA PASIEN DIABETES MELITUS TIPE II RAWAT JALAN NON BPJS DI SERANG TAHUN 2018 TIDAK BERBEDA SIGNIFIKAN

  • Aprilla Ayu Wulandari Universitas Pembangunan Nasional Veteran Jakarta
  • Rika Revina Universitas Pembangunan Nasional Veteran Jakarta
  • Dhigna Luthfiyani Citra Pradana Universitas Pembangunan Nasional Veteran Jakarta
Keywords: OHO Metformin

Abstract

Diabetes mellitus (DM) is one of the four priorities of non-communicable diseases in the world, divided into two types (I and II). The incidence of type II DM in Serang is quite high, there were more than 500 outpatients in 2018, with around 70-100 non BPJS patients. This research was conducted to non BPJS patients, in order to see the difference in the cost of using Oral Hypoglycemic Drugs (OHDs), namely Metformin and Glimepirid. Similar research has never been done by UPN Veterans Jakarta in Serang. This study was an observational analytic study using a cross-sectional approach whose data were taken retrospectively. Subjects were non BPJS type II DM outpatients in 2018, aged 20-65 years, and adhering to treatment using Metformin and Glimepirid. The tools used are paper, stationery, computers, and printers. The materials used are patient data obtained from medical records, pharmaceutical installations, and finance. Data were analysed descriptively and tested its normality with Kolmogorov-Smirnov. The results showed the average cost of using Metformin was Rp 1,209,- while Glimepirid was Rp 1,228,-. So it can be concluded that the cost of using Metformin in outpatient type II DM patients in Serang in 2018, is slightly cheaper than Glimepirid.

References

World Health Organization (WHO), 2015, Diabetes Facts and Number, https://www.who.int/nmh/publications/fact_sheet_diabetes_en.pdf?ua=1. Diakses 11 Januari 2019.

Kementerian Kesehatan Republik Indonesia (Kemenkes RI), 2013, Situasi dan Analisis Diabetes, https:// www.kemkes.go.id/download.php?file= download/pusdatin/infodatin/infodatin-diabetes.pdf, Diakses 8 Januari 2019.

International Diabetes Federation (IDF), 2017, IDF Diabetes Atlas, http:// fmdiabetes.org/wp-content/uploads/ 2018/03/IDF-2017.pdf, Diakses 27 Desember 2018.

Andayani, T.M., 2013, Farmakoekonomi Prinsip dan Metodologi, Bursa Ilmu, Yogyakarta, hal. 13.

Baroroh, F., Solikah, W.Y., dan Urfiyya, Q.’A., 2016, Analisis Biaya Terapi Diabetes Melitus Tipe 2 di Rumah Sakit PKU Muhammadiyah Bantul Yogyakarta, Jurnal Farmasi Sains dan Praktis, Vol. I, No. 2, Hal. 11-22.

Perkumpulan Endokrinologi Indonesia (PERKENI), 2017, Konsensus Pengelolaan dan Pencegahan Diabets Melitus Tipe 2 di Indonesia 2017, http://spesialis1.ika.fk.unair.ac.id/wp-content/uploads/2017/03/Konsensus-Nasional-Pengelolaan-DiabetesNasional -Type-II.pdf, Diakses 27 Desember 2018.

Kementerian Kesehatan Republik Indonesia (Kemenkes RI), 2018, Hari Diabetes Sedunia, https://www. kemkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-diabetes.pdf. Diakses 8 Januari 2019.

Published
2020-05-30
How to Cite
1.
Wulandari A, Revina R, Citra Pradana DL. BIAYA PENGGUNAAN OBAT HIPOGLIKEMIK ORAL (OHO) METFORMIN DAN GLIMEPIRID PADA PASIEN DIABETES MELITUS TIPE II RAWAT JALAN NON BPJS DI SERANG TAHUN 2018 TIDAK BERBEDA SIGNIFIKAN. JIFI [Internet]. 30May2020 [cited 16Jul.2020];3(1):50 -55. Available from: http://jiis.akfar-isfibjm.ac.id/index.php?journal=JIFI&page=article&op=view&path[]=484